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ABSTRACT
Introduction: The first cardiovascular safety trial
in the sodium-glucose co-transporter-2 (SGLT2)
inhibitor drug class, the Empagliflozin Cardio-
vascular Outcomes and Mortality in Type 2 Dia-
betes (EMPA-REG OUTCOME) trial,
demonstrated significant cardiovascular risk
reduction with empagliflozin. It is currently not
clear what proportions of people with type 2 dia-
betes (T2DM) have the same high cardiovascular
risk as those included in the trial, and will there-
fore be likely to experience the same cardiovas-
cular benefit. We aimed to identify and describe
the proportion of people with T2DM from a
representative English national population who
have the comparable high cardiovascular risk to
those included in the EMPA-REG trial.
Method: A cross-sectional analysis of cardio-
vascular risk in people with T2DM and a sub-
group prescribed SGLT2 inhibitors. Patients
were identified from the Royal College of Gen-
eral Practitioners Research and Surveillance
Centre database. Cardiovascular risk factors
were identified from electronic patient records.
Results: From 1,238,909 patients at 128 GP
practices, we identified 60,327 adults with
T2DM (mean age 66.1 years, SD 13.9) of whom
55.6% were male. From these 1642 (2.7%) peo-
ple had been initiated on an SGLT2 inhibitor
(mean age 58.1 years, SD 10.4; 58.8% male). In
the complete T2DM group only 15.7% (95% CI
15.5–16.0%) had the same high cardiovascular
risk as those included in the EMPA-REG trial. In
those already initiated on SGLT2 inhibitors this
proportion was 11.1% (95% CI 9.8–12.4%).
Whilst the proportion was higher in the oldest
age groups, in those 70? years old less than a
quarter met the EMPA-REG trial high cardio-
vascular risk criteria.
Conclusions: The EMPA-REG trial results are
applicable only to a small proportion of people
with T2DM and a smaller proportion of those
currently treated with SGLT2 inhibitors. Addi-
tional data are required to identify any cardio-
vascular benefit in people with lower
cardiovascular risk.
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INTRODUCTION
Until recently there was little evidence for car-
diovascular risk reduction with glucose-lower-
ing therapies in type 2 diabetes (T2DM).
However, within the last year the results of two
trials have demonstrated substantial cardiovas-
cular benefit with two agents: the sodium glu-
cose co-transporter 2 (SGLT2) inhibitor
empagliflozin and then glucagon-like peptide-1
(GLP-1) analogue liraglutide. These landmark
diabetes trials were the Empagliflozin Cardio-
vascular Outcome Event Trial in Type 2 Dia-
betes Mellitus Patients (EMPA-REG OUTCOME)
trial and the Liraglutide Effect and Action in
Diabetes: Evaluation of Cardiovascular Out-
come Results (LEADER) trial, respectively [1, 2].
Whilst ground-breaking, it will take some time
before the full clinical application of these trials
is realized. The EMPA-REG trial was designed as
a non-inferiority randomized placebo-con-
trolled trial to investigate cardiovascular out-
comes and mortality with empagliflozin in a
selected group at very high risk of cardiovascu-
lar disease (Table 1). Unexpectedly, the trial
demonstrated substantial cardiovascular benefit
with empagliflozin in this cohort.
Sodium glucose co-transporter 2 (SGLT2)
inhibitors, also known as gliflozins, improve gly-
cemic control through inhibition of glucose
reuptake by SGLT2 in the proximal tubule of the
kidney [3, 4]. This induces glucosuria which low-
ers serum glucose and also induces diuresis [5].
The cardiovascular risk reduction in the
EMPA-REG trial was observed to occur very early,
with survival curves, compared with placebo,
separating almost immediately after randomiza-
tion [6]. This has led some commentators to
speculate that the survival benefit is achieved not
from glucose lowering but due to the diuretic
effect of SGLT2 inhibition as these survival curves
appear similar to those for trials of diuretics in
people with heart failure [7, 8]. However, the
limited data available do not support this
hypothesis [9]. Alternative mechanisms have
since been suggested including a reduction in
cardiac preload and afterload, or shift towards
myocardial tissue use of a more efficient fuel
(possibly ketone bodies) [10–13]. Additional
experimentation is needed, however, to explore
these further. Given this uncertainty, it is
unknown if the cardiovascular benefits observed
in EMPA-REG can be expected in all people with
T2DM or just those with a similar, high cardio-
vascular risk profile to those people included in
the EMPA-REG trial [10].
The aims of the study were to provide a
description of the cardiovascular risk profile of a
large nationally representative sample of people
with T2DM treated with SGLT2 inhibitors in
England and compare this to the EMPA-REG
trial inclusion criteria. Additionally, we com-
pare those treated with SGLT2 inhibitors with
the wider T2DM population.
METHODS
We performed a cross-sectional analysis of all
people with T2DM included in the Royal Col-
lege of General Practitioners Research and
Surveillance Centre (RCGP RSC) database based
in England, in order to identify people initiated
on SGLT2 inhibitors and describe their cardio-
vascular risk profile. In accordance with our
explicit aim to create high-quality and trans-
parent real-world evidence [14, 15], we have
reported the planned methods in full in the
study protocol [16].
We described the proportion of people with
T2DM currently using SGLT2 inhibitors who
had a similar cardiovascular risk profile to those
included in the EMPA-REG trial. For compar-
ison we also reported the number of people
from the complete T2DM group who had the
same high cardiovascular risk. The use of Eng-
lish electronic health records for this purpose
enabled the identification of a high-quality
population denominator as all individuals are
registered with a single GP practice and have a
unique national identifier, the NHS number
[17]. This enabled capture of an almost com-
plete population without double counting.
At the time of this study, the RCGP RSC
database contained the electronic health
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records from 128 GP practices distributed across
England (1.7% of all practices in England). The
RCGP RSC provided a sample which is repre-
sentative of the UK population [18]. Included
data are recorded using the Read code 5-byte
version 2 coding hierarchy; this comprises
comprehensive diagnosis and treatment infor-
mation, prescriptions, and laboratory data [19].
We used data from all the included GP
practices collated after 1 January 2016. We
included all patients with a diagnosis of T2DM
over 18 years old on or before this date. In those
with T2DM we identified all those people initi-
ated on SGLT2 inhibitors (canagliflozin, dapa-
gliflozin, or empagliflozin) at any time before 1
January 2016.
Table 1 Inclusion criteria for the EMPA-REG trial Excerpted from the supplementary material included in the
EMPA-REG trial manuscript by Zinman et al. [1]
Inclusion criteria
History of myocardial infarction
History of myocardial infarction[2 months prior to informed consent
Coronary artery disease
Evidence of multi-vessel coronary artery disease, i.e., in C2 major coronary arteries or the left main coronary artery,
documented by any of the following:
Presence of signiﬁcant stenosis: C50% luminal narrowing during angiography (coronary or multi-slice computed
tomography)
Previous revascularization (percutaneous transluminal coronary angioplasty ± stent or coronary artery bypass graft
[2 months prior to consent
The combination of revascularization in one major coronary artery and signiﬁcant stenosis (C50% luminal narrowing)
in another major coronary artery
Evidence of single-vessel coronary artery disease, C50% luminal narrowing during angiography (coronary or multi-slice
computed tomography) not subsequently successfully revascularized, with at least 1 of the following:
A positive non-invasive stress test for ischemia
Hospital discharge for unstable angina B12 months prior to consent
Unstable angina
Unstable angina[2 months prior to consent with evidence of single- or multi-vessel coronary artery disease
History of stroke
History of stroke (ischemic or hemorrhagic)[2 months prior to consent
Peripheral artery disease
Occlusive peripheral artery disease documented by any of the following:
Limb angioplasty, stenting, or bypass surgery
Limb or foot amputation due to circulatory insufﬁciency
Evidence of signiﬁcant peripheral artery stenosis ([50% on angiography, or[50% or hemodynamically signiﬁcant via
non-invasive methods) in 1 limb
Ankle brachial index\0.9 in C1 ankle
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We used a two-stage informatics ontol-
ogy-based process [20] to identify people with
T2DM which we have reported in detail else-
where [21]. The two stages were
1. Identification of all people with diabetes
using diabetes diagnosis codes, glucose and
HbA1c test results, or the use of diabetes
therapies
2. Categorization by diabetes type based on
their medication usage history, diabetes
type codes, and other key clinical
characteristics
The clinical characteristics of the whole T2DM
group and subset of people using SGLT2 inhi-
bitors were reported. These comprise age, gen-
der, body mass index (BMI), glycated
hemoglobin (HbA1c), blood pressure, diagnosis
of hypertension, renal function, duration of
diabetes, and current diabetes medications.
BMI was defined using the most recently
recorded values. Where data on BMI were
missing, we calculated BMI from the most
recent weight and height measurements. HbA1c
was defined using the most recent value prior to
the initiation of SGLT2 inhibitor in those on
SGLT2 inhibitors. Blood pressure values were
taken from the most recent measurements. A
diagnosis of hypertension was identified using
diagnostic codes for hypertension only (not
blood pressure measurements).
Renal function was reported as the propor-
tion of people with an estimated glomerular
filtration rate (eGFR) measurement of less than
60 ml/min/1.73 m2. Duration of diabetes was
defined as the time since the first dia-
betes-defining event. These events comprise
first diabetes diagnostic code, first investigation
result consistent with diabetes, or date of first
prescription of glucose-lowering medication.
We have reported the number of people with
missing data for all variables.
The high cardiovascular risk inclusion crite-
ria for the EMPA-REG study are demonstrated in
Table 1. We identified people with each of these
cardiovascular risk factors using clinical diag-
nostic codes, or other codes which identified a
diagnosis of the risk factor (a complete
description of these codes is provided in Sup-
plementary Tables S1 to S6). It is possible that
recording of unstable angina is limited in pri-
mary care data. As a measure of sensitivity we
have also described the number of people with
any recorded code for angina of any severity.
We have considered a person to have the car-
diovascular risk factor of interest if they have
any of the disease-defining codes at any time in
their clinical record.
We have reported the number of people with
each risk factor and proportions with 95%
confidence intervals in those with T2DM and
also in those prescribed SGLT2 inhibitors. We
have also performed subgroup analyses of these
proportions stratified by age group, duration of
diabetes, type of SGLT2 inhibitor, and by
number of current diabetes therapies. Current
diabetes therapies are grouped into none, oral
monotherapy, oral dual therapy, oral triple
therapy (or greater), insulin therapy (any regime
which involves insulin use).
Compliance with Ethics Guidelines
All data to be used was anonymized at the point
of data extraction. No clinically identifiable
information was made available to researchers.
The study has been tested against the Health
Research Authority (HRA)/Medical Research
Council (MRC) ‘‘is this research’’ tool [22] and
was considered to be an audit of current practice
when compared to best available evidence. The
study therefore did not require specific ethical
approval. Approval for this work was granted by
the RCGP RSC study approval committee. This
article is based on previously conducted studies
and does not involve any new studies of human
or animal subjects performed by any of the
authors.
RESULTS
Data were available for analysis from 1,238,909
electronic patient records at 128 general prac-
tices. From these we identified 60,327 adults
with T2DM. This group was slightly older than
the EMPA-REG trial cohort, with a shorter
duration of diabetes, but similar mean BMI
(Table 2). Within this group 1642 (2.7%) people
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Table 2 Characteristics of with T2DM and a subgroup of people using SGLT2 inhibitors in the real world compared with
those in the EMPA-REG trial
Characteristic RCGP RSC total T2DM
group (N5 60,327)
RCGP RSC SGLT2 user
group (N5 1642)
EMPA-REG trial
participants* (N5 4687)
Age (years) 66.1 (±13.9) 58.1 (±10.4) 63.1 (±8.6)
Male 33,535 (55.6) 966 (58.8) 3336 (71.2)
Race
White 42,284 (70.1) 1194 (72.2) 3403 (72.6)
Asian 5706 (9.5) 155 (9.4) 1006 (21.5)
Black 2648 (4.4) 40 (2.4) 237 (5.1)
Other 1109 (1.8) 24 (1.5) 36 (0.8)
Missing 8580 (14.2) 229 (13.9) 5 (0.1)
BMI (kg/m2) 30.7 (±6.5) 34.0 (±6.4) 30.6 (±5.3)
BMI not recorded 1284 (2.1) 9 (0.5) 0 (0.0)
SBP (mmHg) 132.0 (±14.7) 130.2 (±13.4) 135.3 (±16.9)
DBP (mmHg) 75.0 (±9.6) 76.0 (±8.6) 76.6 (±9.7)
BP not recorded 221 (0.4) 2 (0.1) 0 (0.0)
Diagnosed hypertension 35,659 (59.1) 901 (54.9) NR
Uncontrolled hypertension 16,950 (28.1) 373 (22.7) NR
eGFR\60 ml/min/1.73 m2 11,167 (18.5) 76 (4.6) 0 (0.0)
Duration of diabetes
B1 years 5320 (8.8) 45 (2.7) 128 (2.7)
[1–5 years 17,911 (29.7) 314 (19.1) 712 (15.2)
[5–10 years 18,963 (31.4) 604 (36.8) 1175 (25.1)
[10 years 18,133 (30.1) 679 (41.4) 2672 (57.0)
Other glucose-lowering therapy
Metformin 35,146 (58.3) 1416 (30.2) 3459 (73.8)
Insulin 8128 (13.5) 447 (9.5) 2252 (48.0)
Sulfonylurea 14,765 (24.5) 800 (17.1) 2014 (43.0)
Dipeptidyl peptidase-4 inhibitor 7236 (12.0) 605 (12.9) 529 (11.3)
Thiazolidinedione 1875 (3.1) 144 (3.1) 198 (4.2)
Glucagon-like peptide-1 agonist 1983 (3.3) 360 (7.7) 126 (2.7)
Monotherapy 21,284 (35.3) 89 (5.5) 1380 (29.4)
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had been initiated on an SGLT2 inhibitor. The
majority of these were dapagliflozin (1123),
followed by canagliflozin (422), and empagli-
flozin (160), including 63 people who had a
prescription for two different SGLT2 inhibitors.
People initiated on an SGLT2 inhibitor were
younger than those in the EMPA-REG trial, had
a higher BMI, and a broadly similar distribution
of diabetes duration (Table 2). The mean HbA1c
at SGLT2 initiation was 80.0 mmol/mol (SD
17.3). Twenty-eight people (1.7%) had no
HbA1c recorded prior to initiating an SGLT2
inhibitor.
Only a small proportion of people with
T2DM had the same cardiovascular risk factors
as people included in the EMPA-REG trial
(Table 3). Similarly, only a small proportion of
those treated with SGLT2 inhibitors had the
same cardiovascular risk factors as people
included in the EMPA-REG trail (Table 3). A
larger proportion had angina of any severity (all
people with T2DM: 4970 people; 8.2%; 95% CI
8.1–8.4%, those treated with SGLT inhibitors:
128 people; 7.8%; 95% CI 13.2–16.1%) or any
major risk factor or angina of any severity (all
people with T2DM: 11,704 people; 19.4%; 95%
CI 19.1–19.7%, those treated with SGLT inhi-
bitors: 240 people; 14.6%; 95% CI 13.2–16.1%).
In subgroup analyses, the proportion of
people with major cardiovascular risk factors
increased with age but still represented a
minority of people even in the oldest age
groups, i.e., less than a quarter of those over
70 years old (Table 4 and Supplementary
Table S7). The proportion of people with major
cardiovascular risk factors varied little by num-
ber of current oral therapies (none, one, two,
three or more: 14.6%, 14.9%, 14.8%, and
Table 2 continued
Characteristic RCGP RSC total T2DM
group (N5 60,327)
RCGP RSC SGLT2 user
group (N5 1642)
EMPA-REG trial
participants* (N5 4687)
Dual therapy 11,375 (18.9) 448 (27.5) 2259 (48.2)
Data are presented as n (%) or mean (SD)
BMI body mass index, DBP diastolic blood pressure, eGFR estimated glomerular ﬁltration rate, NR not reported, SBP
systolic blood pressure, SD standard deviation
* Pooled empagliﬂozin participants (10 and 25 mg doses)
 Most recent systolic blood pressure C140 mmHg
Table 3 Proportion of people with major cardiovascular risk factors amongst all those with type 2 diabetes (N = 60,327)
and those prescribed an SGLT2 inhibitor (N = 1642)
Cardiovascular risk factor RCGP RSC total T2DM
group (N5 60,327)
RCGP RSC SGLT2 user
group (N5 1642)
Risk factor
present n (%*)
95% conﬁdence
intervals %*
Risk factor
present n (%*)
95% conﬁdence
intervals %*
Myocardial infarction 2978 (4.9) 4.8–5.1 65 (4.0) 3.2–4.8
Coronary artery disease 3542 (5.9) 5.7–6.0 78 (4.8) 3.9–5.6
Unstable angina 528 (0.9) 0.8–0.9 22 (1.3) 0.9–1.8
Stroke 2607 (4.3) 4.2–4.5 44 (2.7) 2.1–3.3
Peripheral artery disease 2679 (4.4) 4.3–4.6 56 (3.4) 2.7–4.1
Any major cardiovascular risk factor 9481 (15.7) 15.5–16.0 182 (11.1) 9.8–12.4
* Percentage of people within group
Diabetes Ther
12.2%, respectively) but was higher in people
on insulin therapy (23.5%) (Supplementary
Table S8). The proportion of people with a
major cardiovascular risk factor was higher in
people with a longer duration of diabetes
(Table 5) with just over 20% prevalence in those
with a history of diabetes longer than 10 years.
The proportion of people with a major cardio-
vascular risk factor was higher in those on
empagliflozin (16.3%) than dapagliflozin
(10.2%) or canagliflozin (12.8%), although the
difference was only significant between empa-
gliflozin and dapagliflozin (Supplementary
Table S9).
DISCUSSION
In a large sample of people with T2DM in Eng-
land only a small proportion (15.7%; 95% CI
15.5–16.0%) had the same high cardiovascular
risk as those included in the EMPA-REG trial. In
those already initiated on SGLT2 inhibitors the
proportion was smaller still (11.1%; 95% CI
9.8–12.4%) and this was a younger group.
Whilst the proportion was higher in the oldest
age groups, even in those 70 years old and over,
this still comprised less than a quarter. Simi-
larly, the proportion was higher in those with
the longest duration of diabetes, but only
comprised just over 20% in those with a dura-
tion of diabetes longer than 10 years.
Implications of the Findings
The cardiovascular benefits identified by the
EMPA-REG trial were a surprising but very wel-
come finding. However, it is important to be
clear that the trial’s participants were selected
on the basis of very high cardiovascular risk. We
can therefore only expect similar cardiovascular
benefits in the same high risk group in the real
world. Our data suggest that this makes up only
a small but not insubstantial proportion of
Table 4 Proportion of people with one or more major cardiovascular risk factor, by age group, amongst all those with type
2 diabetes (N = 60,327)
Age group Number of
people
Number of people with
one or more major
cardiovascular risk factor n (%*)
95% conﬁdence
interval %*
18–49 7526 225 (3.0) 2.7–3.3
50–59 11,145 988 (8.9) 8.4–9.3
60–69 15,643 2273 (14.5) 14.1–15.0
70? 25,971 5995 (23.1) 22.7–23.5
* Percentage of people within age group
Table 5 Proportion of people with one or more major cardiovascular risk factor, by duration of diabetes, amongst all those
with type 2 diabetes (N = 60,327)
Duration of diabetes Number of people Number of people with
one or more major
cardiovascular risk factor n (%*)
95% conﬁdence interval %*
B1 years 5320 613 (11.5) 10.8–12.3
[1–5 years 17,911 2341 (13.1) 12.7–13.5
[5–10 years 18,963 2818 (14.9) 14.4–15.3
[10 years 18,133 3709 (20.5) 20.0–21.0
* Percentage of people within diabetes duration group
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those with T2DM. It also suggests that current
SGLT2 inhibitor use occurs in a subgroup of
people with T2DM who are of a younger age
and have a lower cardiovascular risk than most
people with T2DM. Any cardiovascular benefit
in these people is uncertain. There are also a
large proportion of people with high cardio-
vascular risk who are not currently treated with
an SGLT2 inhibitor. Therefore, there is some
scope to consider extending the use of empa-
gliflozin in people with high cardiovascular risk
if clinically appropriate.
The presence of cardiovascular risk factors
was found, unsurprisingly, to be highest in the
oldest age groups. It is therefore likely that this
group is most likely to gain the largest cardio-
vascular risk reduction from SGLT2 inhibitor
use. However, the use of SGLT2 inhibitors in
this group can be problematic as the elderly are
more likely to experience volume depletion,
more likely to have baseline renal impairment,
and have more significant sequelae from uri-
nary tract infections [23–27].
Other cardiovascular safety trials are still
ongoing and will help to explore questions
around whether these benefits are a class effect
and whether they can also be seen in lower
cardiovascular risk groups. The Multicenter
Trial to Evaluate the Effect of Dapagliflozin on
the Incidence of Cardiovascular Events
(DECLARE-TIMI 58) and CANagliflozin car-
dioVascular Assessment Study (CANVAS) trials
with dapagliflozin and canagliflozin, respec-
tively, are the two major ongoing trials with
currently approved SGLT2 inhibitors [28, 29].
Their inclusion criteria are somewhat broader
than those of the EMPA-REG trial, with lower
cardiovascular risk participants enrolled. Whilst
these trial results are awaited, a comparison of
the characteristics of people treated with T2DM
in clinical practice with those of the EMPA-REG
trial is important to enable an understanding of
how the existing data can be applied in practice.
We provide a description of the cardiovascular
risk profile of a large national sample of people
with T2DM treated with SGLT2 inhibitors in
England and compare this to the EMPA-REG
trial inclusion criteria. We also provide a com-
parison with the complete denominator group
(all people with identified T2DM).
It should be clearly stated that SGLT2 inhi-
bitors have benefits beyond cardiovascular risk
reduction: predominantly improved glycemic
control and weight loss [30]. Our real-world
data demonstrate that people prescribed SGLT2
inhibitors have a higher BMI than others with
T2DM. This trend suggests that the weight loss
benefits of the class are a key consideration in
prescribing. Whilst our analysis demonstrates
that the cardiovascular benefit identified in the
EMPA-REG trial can only be extrapolated to a
small proportion of those currently prescribed
SGLT2 inhibitors, this group will still experi-
ence glycemic and weight loss benefits.
The SGLT2 inhibitor class of medication is
costlier than older therapies. The National
Institute for Health and Care Excellence (NICE)
in the UK has previously undertaken an eco-
nomic analysis of the use of SGLT2 inhibitors
and considers their use to be below the cost-ef-
fectiveness thresholds [31–33]. Otherwise anal-
yses also suggest SGLT2 inhibitors provide
cost-effective benefit [34–36]. The benefits in
these analyses are based on the glucose-lower-
ing potential and do not consider the additional
cardiovascular benefits seen in the EMPA-REG
trial. Although we show that the trial findings
can be only applied directly to a small propor-
tion of those with T2DM, incorporation of the
additional cardiovascular risk reduction into
existing economic models is still likely to
improve the cost–benefit estimates.
Future Research
Our data highlight the importance of further
research to identify any cardiovascular benefit
from SGLT2 inhibitors in lower-risk groups
which make up the majority of SGLT2 inhibitor
use currently. This leads to several important
clinically relevant questions: Are there any car-
diovascular benefits with canagliflozin and
dapagliflozin (which makes up the majority of
SGLT2 inhibitor prescriptions currently)? What,
if any, is the degree of cardiovascular benefit
afforded in the lower cardiovascular risk
groups? The ongoing cardiovascular safety trials
with canagliflozin (CANVAS) and dapagliflozin
(DECLARE-TIMI 58) will go some way to
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answering these questions [28, 29]. The CAN-
VAS trial is estimated to complete in 2017 and
DECLARE-TIMI 58 in 2019. These trials should
be supported by real-world analyses of cardio-
vascular outcomes in people currently treated
with SGLT2 inhibitors.
The EMPA-REG, CANVAS, and DECLAR-
E-TIMI 58 trials also exclude people with certain
comorbidities. Many of those excluded may
have had significant cardiovascular risk. Addi-
tional real-world evidence may also be needed
to clarify whether the use of SGLT2 inhibitors in
those with multimorbidity confers cardiovas-
cular benefit.
Comparison with Similar Studies
Only one other similar study comparing the
EMPA-REG trial inclusion criteria against a large
sample of people with diabetes has been per-
formed. The study in initial reporting, and not
yet published in a complete manuscript, com-
pared the criteria against a large registry-based
population in the USA (the Diabetes Collabo-
rative Registry) [37]. The authors used prior
myocardial infarction, any coronary artery dis-
ease, any coronary revascularization, or
peripheral artery disease to approximate the
EMPA-REG criteria. They found that only 16%
of those with T2DM met these approximate
criteria. These results agree closely with those
presented here. Our present study may provide
a more representative sample of the general
population with T2DM than this registry-based
analysis. We were also able to provide a closer
mapping of disease codes to the EMPA-REG
inclusion criteria than was possible for this
study.
Strengths and Limitations
The key strengths and limitations of the data
source used for the study (RCGP RSC network of
practices) have previously been described
[21, 38] in accordance with European Federa-
tion for Medical Informatics Primary Care
Informatics Working Group consensus recom-
mendations [39]. Key strengths include the
large sample size, high level of data
completeness, and the broadly representative
nature of the population sample. However, the
RCGP RSC group of practices are a somewhat
self-selecting group of GP practices with a
slightly more affluent population than the UK
average [38]. Despite this, given the size of the
population analyzed (ca. 1.7% of the English
population), we feel that these data provide a
reasonable approximation of the UK
population.
Identification of the EMPA-REG inclusion
criteria risk factors from routine primary care
data may be limited by a number of factors.
Firstly, the possibility of missing data (either
because of failure to record known diagnoses or
failure to identify risk factors in clinical prac-
tice) may have led us to underestimate the
number of people who meet these criteria. As
mentioned, our previous analyses of this dataset
have demonstrated a high level of data com-
pleteness, particularly in those with diabetes
which somewhat mitigates this limitation
[21, 38]. Identification of specific inclusion cri-
teria is limited by the clinical coding system
used in UK primary care (Read codes) which
does not have a code which mapped directly
onto each EMPA-REG criterion. We have
therefore used non-specific/broader clinical
codes where no more specific code was avail-
able. This approach may have slightly overesti-
mated the number of people meeting each
inclusion criteria. Generally the Read coding
system is an extensive system which facilitates
very detailed coding of diagnoses and other
code domains [19] such that this mapping
mismatch is limited. Additional limitations of
using routinely collected primary care data in
research have also previously been described
and include the loss of information recorded in
the record as free text [40] which may have led
to some missing cases in our data.
CONCLUSIONS
Extrapolation of the EMPA-REG trial cardiovas-
cular benefits to people with T2DM in the real
world should be performed with extreme cau-
tion. In a large nationally representative sample
of people with T2DM we found that only a
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small proportion of people had the same high
cardiovascular risk as those people included in
the EMPA-REG trial. Additionally, an even
smaller proportion of those currently treated
with SGLT2 inhibitors had the same high risk. It
remains to be seen whether people with T2DM,
multimorbidity, and high cardiovascular risk
(who were excluded from the trials) similarly
benefit from treatment with SGLT2 inhibitors.
Further data are also needed to identify possible
cardiovascular benefit in the remaining lower
cardiovascular risk group.
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